Document:

Exhibit
10.5

 

Oxbridge
Acquisition Corp.

c/o
Suite 201, 42 Edward Street

Georgetown,
Grand Cayman

Cayman
Islands

 

April
12, 2021

 

OAC
Sponsor Ltd.

c/o
Suite 201, 42 Edward Street

Georgetown,
Grand Cayman

Cayman
Islands

 

	 	RE:	Securities
Subscription Agreement

 

Ladies
and Gentlemen:

 

Oxbridge
Acquisition Corp., a Cayman Islands exempted company (the “Company”), is pleased to accept the offer OAC Sponsor Ltd.,
a Cayman Islands exempted company, (the “Subscriber” or “you”) has made to subscribe for 2,875,000
Class B ordinary shares of the Company (the “Shares”), $0.0001 par value per share (the “Class B Shares”),
up to 375,000 of which are subject to complete or partial forfeiture by you if the underwriters of the Company’s initial public
offering (“IPO”) of units (“Units”) do not fully exercise their over-allotment option (the “Over-allotment
Option”). For the purposes of this Agreement, references to “Ordinary Shares” are to, collectively, the
Class B Shares and the Company’s Class A ordinary shares, $0.0001 par value per share (the “Class A Shares”).
Pursuant to the Company’s memorandum and articles of association, as amended to the date hereof (the “Articles”),
Class B Shares will convert into Class A shares on a one-for-one basis, subject to adjustment, upon the terms and conditions set forth
in the Articles. Unless the context otherwise requires, as used herein “Shares” shall be deemed to include any Class A Shares
issued upon conversion of the Class B Shares comprising the Shares. The terms (this “Agreement”) on which the Company
is willing to issue the Shares to the Subscriber, and the Company and the Subscriber’s agreements regarding such Shares, are as
follows:

 

1.
Subscription for Shares.

 

For
the sum of $25,000 (the “Purchase Price”), which the Company acknowledges receiving in cash, the Company hereby issues
the Shares to the Subscriber, and the Subscriber hereby subscribes for the Shares from the Company, subject to forfeiture, on the terms
and subject to the conditions set forth in this Agreement. Concurrently with the Subscriber’s execution of this Agreement, the
Company shall, at its option, deliver to the Subscriber a certificate registered in the Subscriber’s name representing the Shares
(the “Original Certificate”) and update its Register of Members accordingly. All references in this Agreement to shares
of the Company being forfeited shall take effect as surrenders for no consideration of such shares as a matter of Cayman Islands law.
The Subscriber surrenders for no consideration the one Class B Share of the Company currently held by it following the incorporation
of the Company.

 

2.
Representations, Warranties and Agreements.

 

2.1
Subscriber’s Representations, Warranties and Agreements. To induce the Company to issue the Shares to the Subscriber, the
Subscriber hereby represents and warrants to the Company and agrees with the Company as follows:

 

2.1.1
No Government Recommendation or Approval. The Subscriber understands that no federal or state agency has passed upon or made any
recommendation or endorsement of the offering of the Shares.

 

    	 

     

    

 

2.1.2
No Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Subscriber of the transactions
contemplated hereby do not violate, conflict with or constitute a default under (i) the formation and governing documents of the Subscriber,
(ii) any agreement, indenture or instrument to which the Subscriber is a party or (iii) any law, statute, rule or regulation to which
the Subscriber is subject, or any agreement, order, judgment or decree to which the Subscriber is subject.

 

2.1.3
Organization and Authority. The Subscriber is a Cayman Islands exempted company, validly existing and in good standing under the
laws of the Cayman Islands and possesses all requisite power and authority necessary to carry out the transactions contemplated by this
Agreement. Upon execution and delivery by you, this Agreement is a legal, valid and binding agreement of Subscriber, enforceable against
Subscriber in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent
conveyance or similar laws affecting the enforcement of creditors’ rights generally and subject to general principles of equity
(regardless of whether enforcement is sought in a proceeding at law or in equity).

 

2.1.4
Experience, Financial Capability and Suitability. Subscriber is: (i) sophisticated in financial matters and is able to evaluate
the risks and benefits of the investment in the Shares and (ii) able to bear the economic risk of its investment in the Shares for an
indefinite period of time because the Shares have not been registered under the Securities Act (as defined below) and therefore cannot
be sold unless subsequently registered under the Securities Act or an exemption from such registration is available. Subscriber is capable
of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. Subscriber must
bear the economic risk of this investment until the Shares are sold pursuant to: (i) an effective registration statement under the Securities
Act or (ii) an exemption from registration available with respect to such sale. Subscriber is able to bear the economic risks of an investment
in the Shares and to afford a complete loss of Subscriber’s investment in the Shares.

 

2.1.5
Access to Information; Independent Investigation. Prior to the execution of this Agreement, the Subscriber has had the opportunity
to ask questions of and receive answers from representatives of the Company concerning an investment in the Company, as well as the finances,
operations, business and prospects of the Company, and the opportunity to obtain additional information to verify the accuracy of all
information so obtained. In determining whether to make this investment, Subscriber has relied solely on Subscriber’s own knowledge
and understanding of the Company and its business based upon Subscriber’s own due diligence investigation and the information furnished
pursuant to this paragraph. Subscriber understands that no person has been authorized to give any information or to make any representations
which were not furnished pursuant to this Section 2 and Subscriber has not relied on any other representations or information in making
its investment decision, whether written or oral, relating to the Company, its operations and/or its prospects.

 

2.1.6
Regulation D Offering. Subscriber represents that it is an “accredited investor” as such term is defined in Rule 501(a)
of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”) and acknowledges the sale contemplated
hereby is being made in reliance on a private placement exemption to “accredited investors” within the meaning of Section
501(a) of Regulation D under the Securities Act or similar exemptions under state law.

 

2.1.7
Investment Purposes. The Subscriber is purchasing the Shares solely for investment purposes, for the Subscriber’s own account
and not for the account or benefit of any other person, and not with a view towards the distribution or dissemination thereof. The Subscriber
did not decide to enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule
502 under the Securities Act.

 

2.1.8
Restrictions on Transfer; Shell Company. Subscriber understands the Shares are being offered in a transaction not involving a
public offering within the meaning of the Securities Act. Subscriber understands the Shares will be “restricted securities”
within the meaning of Rule 144(a)(3) under the Securities Act and Subscriber understands that the certificates or book-entries representing
the Shares will contain a legend in respect of such restrictions. If in the future the Subscriber decides to offer, resell, pledge or
otherwise transfer the Shares, such Shares may be offered, resold, pledged or otherwise transferred only pursuant to: (i) registration
under the Securities Act, or (ii) an available exemption from registration. Subscriber agrees that if any transfer of its Shares or any
interest therein is proposed to be made, as a condition precedent to any such transfer, Subscriber may be required to deliver to the
Company an opinion of counsel satisfactory to the Company. Absent registration or an exemption, the Subscriber agrees not to resell the
Shares. Subscriber further acknowledges that because the Company is a shell company, Rule 144 may not be available to the Subscriber
for the resale of the Shares until one year following consummation of the initial business combination of the Company, despite technical
compliance with the requirements of Rule 144 and the release or waiver of any contractual transfer restrictions.

 

    	 

     

    

 

2.1.9
No Governmental Consents. No governmental, administrative or other third party consents or approvals are required, necessary or
appropriate on the part of Subscriber in connection with the transactions contemplated by this Agreement.

 

2.2
Company’s Representations, Warranties and Agreements. To induce the Subscriber to purchase the Shares, the Company hereby
represents and warrants to the Subscriber and agrees with the Subscriber as follows:

 

2.2.1
Incorporation and Corporate Power. The Company is a Cayman Islands exempted company and is qualified to do business in every jurisdiction
in which the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating
results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to carry out the transactions
contemplated by this Agreement.

 

2.2.2
No Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Company of the transactions
contemplated hereby do not violate, conflict with or constitute a default under (i) the Memorandum and Articles of Association of the
Company, (ii) any agreement, indenture or instrument to which the Company is a party or (iii) any law, statute, rule or regulation to
which the Company is subject, or any agreement, order, judgment or decree to which the Company is subject.

 

2.2.3
Title to Shares. Upon issuance in accordance with, and payment pursuant to, the terms hereof, and registration on the register
of members of the Company, the Shares will be duly and validly issued, fully paid and nonassessable. Upon issuance in accordance with,
and payment pursuant to, the terms hereof the Subscriber will have or receive good title to the Shares, free and clear of all liens,
claims and encumbrances of any kind, other than (a) transfer restrictions hereunder and under the other agreements to which the Shares
may be subject, (b) transfer restrictions under federal and state securities laws, and (c) liens, claims or encumbrances imposed due
to the actions of the Subscriber.

 

2.2.4
No Adverse Actions. There are no actions, suits, investigations or proceedings pending, threatened against or affecting the Company
which: (i) seek to restrain, enjoin, prevent the consummation of or otherwise affect the transactions contemplated by this Agreement
or (ii) question the validity or legality of any transactions or seeks to recover damages or to obtain other relief in connection with
any transactions.

 

2.2.5
Authorization. The Class A Shares issuable upon conversion of the Class B Shares have been duly authorized and reserved for issuance
upon such conversion.

 

3.
Forfeiture of Shares.

 

3.1
Partial or No Exercise of the Over-allotment Option. In the event the Over-allotment Option granted to the underwriters of the
IPO is not exercised in full, the Subscriber acknowledges and agrees that it (and, if applicable, any transferee of Shares) shall forfeit
any and all rights to such number of Shares (up to an aggregate of 375,000 Shares and pro rata based upon the percentage of the Over-allotment
Option exercised) such that immediately following such forfeiture, the Subscriber (and any such transferees) will own an aggregate number
of Shares (not including Class A Shares issuable upon exercise of any warrants or any securities purchased by Subscriber in the IPO or
in the aftermarket) equal to 20% of the issued and outstanding Ordinary Shares immediately following the IPO.

 

3.2
Termination of Rights as Shareholder. If any of the Shares are forfeited in accordance with this Section 3, then after such time
the Subscriber (or successor in interest), shall no longer have any rights as a holder of such forfeited Shares, and the Company shall
take such action as is appropriate to cancel such forfeited Shares.

 

    	 

     

    

 

3.3
Share Certificates. In the event an adjustment to the Original Certificate, if any, is required pursuant to this Section 3, then
the Subscriber shall return such Original Certificate to the Company or its designated agent as soon as practicable upon its receipt
of notice from the Company advising Subscriber of such adjustment, following which a new certificate (the “New Certificate”),
if any, shall be issued in such amount representing the adjusted number of Shares held by the Subscriber. The New Certificate, if any,
shall be returned to the Subscriber as soon as practicable. Any such adjustment for any uncertificated securities held by the Subscriber
shall be made in book-entry form.

 

4.
Waiver of Liquidation Distributions; Redemption Rights.

 

In
connection with the Shares purchased pursuant to this Agreement, the Subscriber hereby waives any and all right, title, interest or claim
of any kind in or to any distributions by the Company from the trust account which will be established for the benefit of the Company’s
public shareholders and into which substantially all of the proceeds of the IPO will be deposited (the “Trust Account”),
in the event of a liquidation of the Company upon the Company’s failure to timely complete an initial business combination. For
purposes of clarity, in the event the Subscriber purchases securities in the IPO or in the aftermarket, any Class A Shares so purchased
shall be eligible to receive any liquidating distributions by the Company. However, in no event will the Subscriber have the right to
redeem any Ordinary Shares held by it into funds held in the Trust Account upon the successful completion of an initial business combination.

 

5.
Restrictions on Transfer.

 

5.1
Securities Law Restrictions. In addition to any restrictions to be contained in that certain letter agreement (commonly known
as an “Insider Letter”) dated on or prior to the closing of the IPO by and between Subscriber and the Company, Subscriber
agrees not to sell, transfer, pledge, hypothecate or otherwise dispose of all or any part of the Shares unless, prior thereto (a) a registration
statement on the appropriate form under the Securities Act and applicable state securities laws with respect to the Shares proposed to
be transferred shall then be effective or (b) the Company has received an opinion from counsel reasonably satisfactory to the Company,
that such registration is not required because such transaction is exempt from registration under the Securities Act and the rules promulgated
by the Securities and Exchange Commission thereunder and with all applicable state securities laws.

 

5.2
Lock-up. Subscriber acknowledges that the Shares will be subject to lock-up provisions (the “Lock-up”) contained
in the Insider Letter. Pursuant to the Insider Letter, Subscriber will agree (subject to certain exceptions) not to sell, transfer, pledge,
hypothecate or otherwise dispose of all or any part of the Shares until the earlier to occur of: (A) one year after the completion of
the Company’s initial business combination or (B) the date on which the Company completes a liquidation, merger, stock exchange
or other similar transaction after its initial business combination that results in all of its shareholders having the right to exchange
their Ordinary Shares for cash, securities or other property. Notwithstanding the foregoing, if the last sale price of the Class A Shares
equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for
any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s initial business combination,
the Shares will be released from the Lock-up.

 

5.3
Restrictive Legends. All certificates representing the Shares shall have endorsed thereon legends substantially as follows:

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES
LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH,
IN THE OPINION OF COUNSEL, IS AVAILABLE.”

 

    	 

     

    

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCKUP AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED
DURING THE TERM OF THE LOCKUP.”

 

5.4
Additional Shares or Substituted Securities. In the event of the declaration of a share dividend, the declaration of an extraordinary
dividend payable in a form other than Shares, a spin-off, a share split, an adjustment in conversion ratio, a recapitalization or a similar
transaction affecting the Company’s outstanding Ordinary Shares without receipt of consideration, any new, substituted or additional
securities or other property which are by reason of such transaction distributed with respect to any Shares subject to this Section 5
or into which such Shares thereby become convertible shall immediately be subject to this Section 5 and Section 3. Appropriate adjustments
to reflect the distribution of such securities or property shall be made to the number and/or class of Ordinary Shares subject to this
Section 5 and Section 3.

 

5.5
Registration Rights. Subscriber acknowledges that the Shares are being purchased pursuant to an exemption from the registration
requirements of the Securities Act and will become freely tradable only after certain conditions are met or they are registered pursuant
to a registration rights agreement to be entered into with the Company prior to the closing of the IPO (the “Registration Rights
Agreement”).

 

6.
Other Agreements.

 

6.1
Further Assurances. Subscriber agrees to execute such further instruments and to take such further action as may reasonably be
necessary to carry out the intent of this Agreement.

 

6.2
Notices. All notices, statements or other documents which are required or contemplated by this Agreement shall be: (i) in writing
and delivered personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission
to the address designated in writing, (ii) by facsimile to the number most recently provided to such party or such other address or fax
number as may be designated in writing by such party and (iii) by electronic mail, to the electronic mail address most recently provided
to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication
so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt
of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier
service or five (5) days after mailing if sent by mail.

 

6.3
Entire Agreement. This Agreement, together with that certain Insider Letter to be entered into between Subscriber and the Company
and the Registration Rights Agreement, each substantially in the form to be filed as an exhibit to the Registration Statement, embodies
the entire agreement and understanding between the Subscriber and the Company with respect to the subject matter hereof and supersedes
all prior oral or written agreements and understandings relating to the subject matter hereof.

 

6.4
Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement
executed by all parties hereto.

 

6.5
Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted,
only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall
be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not
similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and
shall not constitute a continuing waiver or consent.

 

6.6
Assignment. The rights and obligations under this Agreement may not be assigned by either party hereto without the prior written
consent of the other party.

 

6.7
Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties
hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement
shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as
a third-party beneficiary of this Agreement.

 

    	 

     

    

 

6.8
Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and
governed by the laws of New York applicable to contracts wholly performed within the borders of such state, without giving effect to
the conflict of law principles thereof.

 

6.9
Severability. In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof,
contained in this Agreement shall be unreasonable or unenforceable in any respect, then such provision shall be deemed limited to the
extent that such court deems it reasonable and enforceable, and as so limited shall remain in full force and effect. In the event that
such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall
nevertheless remain in full force and effect.

 

6.10
No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under
this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of
such party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or
discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof
or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver
of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement
shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or
constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without
such notice or demand.

 

6.11
Survival of Representations and Warranties. All representations and warranties made by the parties hereto in this Agreement or
in any other agreement, certificate or instrument provided for or contemplated hereby, shall survive the execution and delivery hereof
and any investigations made by or on behalf of the parties.

 

6.12
No Broker or Finder. Each of the parties hereto represents and warrants to the other that no broker, finder or other financial
consultant has acted on its behalf in connection with this Agreement or the transactions contemplated hereby in such a way as to create
any liability on the other. Each of the parties hereto agrees to indemnify and save the other harmless from any claim or demand for commission
or other compensation by any broker, finder, financial consultant or similar agent claiming to have been employed by or on behalf of
such party and to bear the cost of legal expenses incurred in defending against any such claim.

 

6.13
Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference
only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

6.14
Counterparts. This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party,
it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or any other form of electronic delivery, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

6.15
Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity
or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption
or burden of proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement.
The words “include,” “includes,” and “including” will be deemed to be followed
by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be construed to include any other
gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires.
The words “this Agreement,” “herein,” “hereof,” “hereby,”
“hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular subdivision
unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will have independent
significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that
there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity)
which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first
representation, warranty, or covenant.

 

    	 

     

    

 

6.16
Mutual Drafting. This Agreement is the joint product of the Subscriber and the Company and each provision hereof has been subject
to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.

 

7.
Voting and Tender of Shares.

 

Subscriber
agrees to vote the Shares in favor of an initial business combination that the Company negotiates and submits for approval to the Company’s
shareholders and shall not seek redemption with respect to any of the Shares. Additionally, the Subscriber agrees not to tender any Shares
in connection with a tender offer presented to the Company’s shareholders in connection with an initial business combination negotiated
by the Company.

 

8.
Indemnification.

 

Each
party shall indemnify the other against any loss, cost or damages (including reasonable attorney’s fees and expenses) incurred
as a result of such party’s breach of any representation, warranty, covenant or agreement in this Agreement.

 

[Signature
Page Follows]

 

    	 

     

    

 

If
the foregoing accurately sets forth our understanding and agreement, please sign the enclosed copy of the Agreement and return it to
us.

 

	 	Very truly yours,
	 	 
	 	Oxbridge Acquisition Corp.
	 	 	 
	 	By:	/s/ Jay
    Madhu
	 	Name:	Jay Madhu
	 	Title:	Chief Executive Officer and Director
	 	 	 
	 	Accepted and agreed, April 12, 2021
	 	 
	 	OAC Sponsor Ltd.
	 	 	 
	 	By:	/s/ Jay
    Madhu
	 	Name:	Jay Madhu
	 	Title:	Director

 

[Signature
page to Subscription Agreement]EX-10.19

 Exhibit 10.19 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private
or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

CONFIDENTIAL 
 LEASEBACK
AGREEMENT 
 This Leaseback Agreement (the “Agreement”), is executed on June 16, 2021 (“Effective
Date”), by and between Intellia Therapeutics, Inc., located at 40 Erie Street, Cambridge, MA 02139 (“Intellia”), and Caribou Biosciences, Inc., located at 2929 7th St.
Suite 105, Berkeley, CA 94710 (“Caribou”) (Intellia and Caribou are each individually a “Party” and together the “Parties”). 

WHEREAS, the Parties disputed whether certain technology, including CRISPR-Cas9 hybrid RNA DNA guides as set forth in U.S. and foreign pending
patent applications and issued patents claiming priority, directly or indirectly, to U.S. Provisional Application No. 62/251,548, filed November 5, 2015, and U.S. Provisional Application No. 62/108,931, filed January 28, 2015
(the “Cas9 chRDNA Patent Rights”) (“Cas9 chRDNAs”), were included within the scope of the rights exclusively licensed by Caribou to Intellia pursuant the License Agreement, dated July 16, 2014, as amended (the
“Caribou-Intellia License Agreement”); 
 WHEREAS, in light of that dispute, Intellia initiated an arbitration proceeding
before a panel of arbitrators (the “Panel”) pursuant to Section 8.1(c) of the Caribou-Intellia License Agreement, and the Panel issued an Interim Award in September of 2019 [***] (such rights [***], the “Leaseback
Rights”); 
 [***] 

NOW, THEREFORE, the Parties agree as follows as to the terms and conditions governing the Leaseback Rights, based on the Panel’s Interim
Award, orders, and additional guidance: 
  

	1.	 Any defined term used but not independently defined herein shall have the meaning given to such term in the
Caribou-Intellia License Agreement. 

  

	2.	 Subject to the terms and conditions of this Agreement, Intellia hereby grants to Caribou the exclusive (even as
to Intellia), worldwide right to develop and commercialize the CB-010 Product (as defined below) under a “leaseback” solely of the patent rights licensed from Caribou to Intellia under the
Caribou-Intellia License Agreement, including the Cas9 chRDNA Patent Rights, with the right to sublicense through multiple tiers for the purpose of the development and commercialization of such CB-010 Product.
For purposes of this Agreement, “leaseback” has the same meaning as “sublicense” does under applicable law in reference to patent rights. Other than as expressly provided herein, Intellia does not grant any rights, licenses, or
leases under this Agreement, whether by implication, estoppel or otherwise, including without limitation any rights, licenses, or leases in regard to any patents owned by Intellia or its Affiliates. 

 

	 	a.	 [***] 

  

	3.	 “CB-010 Product” means the product described in
Caribou’s Investigational New Drug (“IND”) application cleared by the U.S. Food and Drug Administration (“FDA”) on [***], entitled “CB-010; Allogeneic T cells
transduced with adeno-associated virus serotype 6 (AAV-6) expressing CRISPR-Cas9 gene-edited CD19 chimeric antigen receptor (CAR),” as well as modifications permitted under the same IND. [***].
Notwithstanding the foregoing, the CB-010 Product includes additional indications and patient populations for the CB-010 Product (and the permitted modifications
discussed above), even if obtaining approval for such additional indications and patient populations requires separate (i.e., a separate BLA) or supplementary regulatory filings. “Leaseback Product” shall mean the CB-010 Product. 

  
 1 

	4.	 The “Leaseback Payments” are the following payments from Caribou to Intellia:

  

	 	a.	 Upfront payment. Within [***] of the Effective Date of this Agreement, Caribou will pay Intellia $1,000,000.

  

	 	b.	 Milestone Payments. 

  

	 	i.	 Unless earlier terminated pursuant to Section 6.a of this Agreement, until the expiration, abandonment, or
invalidation of the last claim within the Cas9 chRDNA Patent Rights (the “Term”) and for the following events (each, a “Milestone”), Caribou will pay to Intellia the following milestone payments (each, a
“Milestone Payment”) within [***] after the Milestone occurs. Milestones may be met by Caribou, its Affiliates, joint ventures, or Sublicensees thereof. Each Milestone Payment is only due once, even if a Milestone occurs more than
once. 

  

	 	•	 	 [***] 

  

	 	ii.	 “Affiliate” of a Person means any other Person which (directly or indirectly) is controlled
by, controls or is under common control with such Person, but only for so long as such entity is controlled by, controls or is under common control with such Person. For purposes of this definition, “control” (including the terms
“controlled by” and “under common control with”), with respect to the relationship between or among two or more Persons, shall mean (a) with respect to a corporate entity direct or indirect ownership of 50% or more (or, if
less than 50%, the maximum ownership interest permitted by applicable law) of the stock or shares having the right to vote for the election of directors of such corporate entity or (b) with respect to an entity that is not a corporation the
power to direct or cause the direction of the affairs or management of a Person, whether through the ownership of voting securities, as trustee, personal representative or executor, by contract or otherwise, including, without limitation, the
ownership, directly or indirectly, of securities having the power to elect a majority of the board of directors or similar body governing the affairs of such Person; provided however that, pursuant to a Caribou and Intellia written agreement,
“Affiliate” may also include joint ventures, whether corporations or not, between a Party and one or more other Persons formed to exploit one or more Leaseback Products (and related activities). “Affiliates” shall not include any
financial investors of a Party or any of its Affiliates. 

  

	 	iii.	 “Sublicensee” means any Person that is granted a sublicense as permitted by Section 2.a
of this Agreement either (a) directly by a Party or (b) indirectly by any Person granted rights by a Party pursuant to Section 2.a of this Agreement. 

 

	 	iv.	 “Net Sales” means the total gross amount invoiced by Caribou on the worldwide sale of
Leaseback Products by Caribou, its Affiliates, or Sublicensees to third parties for the manufacture, use, sale, rental, or lease of Leaseback Products [***]. Any sales among Caribou, Affiliates, and Sublicensees should be excluded when calculating
Net Sales, provided that any resale to third parties shall be included. 

  

	 	c.	 Royalties. 

  

	 	i.	 During the Term, Caribou will pay to Intellia royalties on Annual Net Sales (“Royalties”) as
set forth below: 

 [***] 
  

	 	ii.	 [***] 

  

	 	iii.	 Royalties will be due on a quarterly basis within [***] after the end of each applicable calendar quarter and
will be accompanied by a royalty report showing the calculation of the royalty. Caribou will keep complete, true and accurate books of account and records for the purpose of showing the derivation of all Royalties. Such records will be sufficient to
permit Intellia, through its independent auditor (reasonably acceptable to Caribou) (“Intellia’s Auditor”), to 

  
 2 

	 	
confirm the accuracy of any royalty reports. Caribou will keep such books and records for at least [***] following the end of the period to which they pertain. Intellia will have the right, at
its expense, and on reasonable prior written notice to Caribou and no more than once per calendar year (unless the previous audit showed a discrepancy), to request and receive such records be sent to Intellia’s Auditor electronically, by
courier, or be presented in person (during Caribou’s normal business hours) solely to verify any reports and payments made hereunder. In the event any inspection performed under this Section 4.c.iii reveals an underpayment, Caribou will
remit the amount of such underpayment within [***] after receiving written notice of such underpayment. [***]. 

  

	 	iv.	 All payments to Intellia under the terms of this Agreement will be in U.S. Dollars. Amounts received by
Caribou, its Affiliates and Sublicensees in currency other than U.S. Dollars will be converted to U.S. Dollars for purposes of calculating Net Sales according to the same conversion rates that Caribou uses for its own internal business operations,
consistently applied, or, if Caribou does not have such a conversion rate for a given currency, then at the rates published in The Wall Street Journal for the day when the applicable payment was received. 

 

	 	v.	 All tax payments required on royalty payments from sales of Leaseback Products (other than income tax
obligations of Intellia) will be paid by Caribou and will not be deducted from the royalty payments or other payments due to Intellia; and in any event the royalty amounts payable hereunder will be increased by the amount of any such deductions. To
the extent permitted under applicable law, the Parties will use diligent efforts to utilize any exemption available to minimize any taxes, fees or other charges imposed on the payment of royalties and other payments under the terms of this
Agreement. 

  

	5.	 [***] 

  

	 	a.	 [***] 

  

	 	b.	 [***] 

  

	 	c.	 [***] 

  

	 	d.	 [***] 

  

	6.	 Representations, Warranties and Covenants. 

 

	 	a.	 [***] 

  

	 	b.	 [***] 

  

	7.	 Dispute Resolution, Governing Law and Venue. 

 

	 	a.	 Disputes of any nature arising under, relating to, or in connection with this Agreement shall be resolved under
the terms of Section 8.1 (Dispute Resolution) of the Caribou-Intellia License Agreement. 

  

	 	b.	 This Agreement will be governed by, and construed in accordance with, the substantive laws of the State of New
York, without giving effect to any choice or conflict of law provision, except that questions affecting the validity and enforceability of any patent will be determined by the law of the country in which the patent will have been granted. [***].

  

	8.	 This Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a
written instrument executed by each Party or, in the case of waiver, by the Party waiving compliance. The delay or failure of either Party at any time or times to require performance of any provisions hereof will in no manner affect the rights at a
later time to enforce the same. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, will be deemed to be, or considered as, a further or
continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 

  
 3 

	9.	 Rights and responsibilities with regard to prosecution, maintenance, enforcement, and defense of the patents
subject to the Leaseback Rights are as set forth in the Caribou-Intellia License Agreement, including rights and responsibilities existing prior to the Effective Date of this Agreement. 

 

	10.	 This Agreement embodies the entire understanding of the Parties with respect to the specific subject matter
addressed herein, and supersedes and merges any other oral or written communications or understandings concerning such subject matter. For clarity, however, the Caribou-Intellia License Agreement and the Memorandum of Understanding, dated
March 14, 2019, between Caribou and Intellia remain in full force and effect. Further, this Agreement incorporates by reference the confidentiality provisions set out in Section 5 of the Caribou-Intellia License Agreement. In addition, any
press releases relating to this Agreement are governed by the terms of Section 5.5(c) of the Caribou-Intellia License Agreement (except the first sentence of such section), applied to this Agreement. 

 

	11.	 Should one or more provisions of this Agreement be or become invalid, then the Parties hereto will attempt to
agree upon valid provisions in substitution for the invalid provisions, which in their economic effect come so close to the invalid provisions that it can be reasonably assumed that the Parties would have accepted this Agreement with those new
provisions. If the Parties are unable to agree on such valid provisions, the invalidity of such one or more provisions of this Agreement will not affect the validity of the Agreement as a whole, unless the invalid provisions are of such essential
importance for this Agreement that it may be reasonably presumed that the Parties would not have entered into this Agreement without the invalid provisions. 

  

	12.	 Neither Party may assign this Agreement or any of its rights under this Agreement or (except as otherwise
expressly provided in this Agreement) delegate its performance under this Agreement, except to any Third Party successor to all or substantially all of the assets or business of such Party to which this Agreement relates, whether in a merger, sale
of stock, sale of assets, reorganization or other transaction. Any purported assignment and/or delegation by a Party in contravention of this Section 12 will, at the option of the other Party, be null and void and of no effect. No assignment
will release either Party from responsibility for the performance of any accrued obligation of such Party hereunder. This Agreement will be binding upon and enforceable against the administrators, legal representatives, and successors of the
Parties. 

  

	13.	 This Agreement may be executed in counterparts, each of which will be deemed to be original and both of which
will constitute one and the same Agreement. 

  

	14.	 Nothing herein contained will be deemed to create an agency, joint venture, amalgamation, partnership or
similar relationship between Caribou and Intellia and their respective Affiliates. Notwithstanding any of the provisions of this Agreement, neither Party to this Agreement will at any time enter into, incur, or hold itself out to Third Parties as
having authority to enter into or incur, on behalf of the other Party, any commitment, expense, or liability whatsoever, and all contracts, expenses and liabilities in connection with or relating to the obligations of each Party under this Agreement
will be made, paid, and undertaken exclusively by such Party on its own behalf and not as an agent or representative of the other. 

  

	15.	 All notices, requests, demands and other communications between the Parties with respect to any of the
provisions of this Agreement will be sent to the addresses set out below, or to such other addresses as may be designated by one Party to the other by notice pursuant hereto, by internationally recognized courier (e.g., FedEx, DHL, etc.),
with receipt signature required to the addresses set out below: 

 Intellia Therapeutics 

40 Erie Street 
 Cambridge, MA
02139 
 Attn: General Counsel 

NTLANotice@intelliatx.com 

  
 4 

 Caribou Biosciences, Inc. 

2929 7th Street, Suite 105 

Berkeley, CA 94710 
 Attn: Chief
Legal Officer 
 legalnotices@cariboubio.com 
  

	16.	 Neither Caribou nor Intellia will be liable for failure of or delay in performing obligations set forth in this
Agreement, and neither will be deemed in breach of such obligations, if such failure or delay is due to natural disasters or any causes reasonably beyond the control of the affected Party (each, a “Force Majeure Condition”);
provided that the Party affected will promptly notify the other of the Force Majeure Condition and will exert all reasonable efforts to eliminate, cure or overcome any such causes and to resume performance of its obligations as soon as
possible. 

  

	17.	 Each of Caribou and Intellia acknowledges and agrees that this Agreement represents the settlement of disputed
claims asserted by each Party with respect to the subject matter outlined herein. Without limiting the foregoing, neither Caribou nor Intellia will appeal or otherwise contest the Panel’s rulings and guidance. 

IN WITNESS WHEREOF, the Parties have caused this Leaseback Agreement to be executed by their respective authorized representatives as of the
Effective Date. 
  

									
	INTELLIA THERAPEUTICS, INC.	 	 	 	CARIBOU BIOSCIENCES, INC.
					
	By	 	 /s/ José Rivera
	 		 	By	 	 /s/ Rachel E. Haurwitz

	Name:	 	 Jose Rivera
	 		 	Name:	 	 Rachel E. Haurwitz

	Title:	 	 EVP, General Counsel
	 		 	Title:	 	 President and CEO

	Date:	 	 6/16/2021
	 		 	Date:	 	 6/16/2021

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]